Site-of-Care Shift for Physician-Administered Drug Therapies: Update
BRG is home to renowned thought leaders and experts considered authorities in their fields of work. Our timely research and perspectives provide analysis and insights on the most important issues facing the industries and organizations we serve.
In October 2017, BRG professionals published a white paper evaluating the breakdown in site of care for top drugs used to treat several conditions (breast cancer, rheumatoid arthritis, and multiple myeloma). The paper analyzed data on physician-administered medicines covered by Medicare Part B and found that as of 2015, nearly one-third of Medicare Part B drug reimbursement for breast cancer and multiple myeloma treatments, and nearly 19 percent for rheumatoid arthritis treatments, occurred in the 340B hospital setting. For all three conditions, historical trends indicated a significant shift in site of care since 2008.
This paper updates the prior analysis to reflect Medicare claims data through 2017 and provide a broader view of all Part B drugs. This paper also compares the total size of the 340B Drug Discount Program to the total size of Part B drug sales, both measured at wholesale acquisition cost (WAC), and provides an updated analysis of the impact of the Centers for Medicare and Medicaid Services’ (CMS) cut in reimbursement for most 340B-purchased Part B drugs.
This study was funded by the Pharmaceutical Research and Manufacturers of America.
Related Professionals
Prepare for what's next.
ThinkSet magazine, a BRG publication, provides nuanced, multifaceted thinking and expert guidance that help today’s business leaders adopt a more strategic, long-term mindset to prepare for what’s next.